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Abstract
Background: Duchenne muscular dystrophy (DMD) cardiomyopathy is a progressive disease for which there is no
cure. Disease-specific therapies are needed that can be initiated before irreversible myocardial damage ensues. In
order to evaluate therapeutic efficacy, surrogate endpoints other than ejection fraction must be found. The
hypothesis of this study is that T1 and extracellular volume fraction (ECV) mapping using cardiovascular magnetic
resonance (CMR) can detect diffuse extracellular matrix expansion in DMD patients with normal left ventricular
ejection fraction (LVEF) and without myocardial late gadolinium enhancement (LGE).
Methods: Thirty-one DMD and 11 healthy control participants were prospectively enrolled. CMR using a modified
Look-Locker (MOLLI) sequence was performed in all participants before and after contrast administration. T1 and
ECV maps of the mid left ventricular myocardium were generated and regions of interest were contoured using the
standard 6-segment AHA model. Global and segmental values were compared between DMD and controls using a
Wilcoxon rank-sum test.
Results: The DMD participants had significantly higher mean native T1 compared with controls (1045 ms vs 988 ms,
p = 0.001). DMD participants with normal LVEF and without evidence of LGE also demonstrated elevated mean native
T1 (1039 ms vs 988 ms, p = 0.002, and 1038 ms vs 988 ms, p = 0.011). DMD participants had a significantly greater mean
ECV than controls (0.31 vs 0.24, p < 0.001), even in the settings of normal LVEF (0.28 vs 0.24, p < 0.001) and negative LGE
(0.29 vs 0.24, p = 0.001).
Conclusions: DMD participants have elevated LV myocardial native T1 and ECV, even in the setting of normal LVEF
and in the absence of LGE. T1 and ECV mapping in DMD have potential to serve as surrogate cardiomyopathy
outcome measures for clinical trials.
Keywords: Duchenne muscular dystrophy, Cardiomyopathy, Cardiovascular magnetic resonance, Extracellular volume
fraction, T1 mapping
Background
Duchenne muscular dystrophy (DMD) affects 1 in 4700
live male births [1]. DMD is a progressive disease lead-
ing to skeletal and cardiac myopathy. The development
of cardiomyopathy, defined here as abnormal ejection
fraction, occurs in the majority of boys with DMD by
18 years of age [2]. With improvements in supportive
care measures that mitigate the complications of skeletal
muscle disease, cardiovascular disease has become the
leading cause of death [3]. Standard heart failure medi-
cations, such as angiotensin converting enzyme inhibi-
tors and beta-blockers, confer some benefits, but
ultimately only delay the inexorable decline in cardiac
function [4, 5]. More effective DMD-specific therapies
are necessary to reduce the morbidity and mortality as-
sociated with DMD cardiomyopathy [5]. Evaluation of
therapeutic efficacy, however, is difficult. Assuming a
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study treatment is initiated early enough in the disease
course to have maximal effect, it could take over a dec-
ade of therapy to reach traditional study trial endpoints
such as reduced left ventricular ejection fraction (LVEF).
Earlier, non-invasive biomarkers of cardiac disease pro-
gression are integral to the ongoing clinical care of these
patients and to the evaluation of therapeutic alternatives
for DMD.
Pathological studies demonstrate significant fibrosis in
DMD myocardium that usually begins in the subepicar-
dium of the left ventricular (LV) free wall [6]. Late gadolin-
ium enhancement (LGE) using cardiovascular magnetic
resonance (CMR) can reveal extracellular matrix (ECM)
expansion consistent with fibrosis in the same location,
[7, 8] but quantification of LGE in DMD can be difficult
[9]. LGE is best for detection of focal areas of ECM ex-
pansion, not the diffuse ECM expansion found in boys
with DMD [10–12]. In addition, by the time larger areas
of ECM expansion are detectable by LGE, it may be too
late to reverse the myocardial damage.
CMR mapping of the myocardial longitudinal relax-
ation time constant, T1, can reveal myocardial abnor-
malities such as fibrosis and edema. Previously, we used
a retrospective analysis to report elevated post-contrast
T1 times in boys with DMD [13]. T1 measurements can
be used to calculate the myocardial extracellular volume
fraction (ECV), a quantitative technique that allows esti-
mation of ECM expansion [14]. Pathological studies have
demonstrated a strong correlation between ECV and
ECM expansion caused by fibrosis and edema [12, 15–17].
Studies have reported elevated ECV in multiple myocar-
dial disease processes and ECV can predict mortality
[18, 19]. A single study in a cohort of Becker muscular
dystrophy patients demonstrated elevated ECV when
compared with controls [20]. However, to our knowledge,
no published studies have evaluated ECV in patients with
DMD. We hypothesized that the diffuse ECM expansion
found in DMD is detectable using T1 and ECV mapping,
even in the absence of standard measures of myocardial
disease such as abnormal LVEF and LGE.
Methods
Patient selection
This single-center, prospective, observational study was
approved by the Vanderbilt University Institutional Review
Board and completed between January 2013 and July 2015.
Consent was obtained for all participants; those under
18 years of age signed an age-appropriate assent form. Partic-
ipants in the DMD group were recruited from the multidis-
ciplinary Neuromuscular-Cardiology Clinic and were over
7 years of age. The diagnosis of DMD was confirmed by ei-
ther skeletal muscle biopsy or the presence of a dystrophin
mutation and skeletal muscle weakness. Exclusion criteria
were: requiring sedation for CMR, renal dysfunction or other
contraindication to contrast-enhanced CMR.
Healthy participants aged 18–30 with a body mass index
ranging from 18 to 25 kg/m2 were recruited into the con-
trol group. Exclusion criteria were: cardiovascular disease
(including but not limited to congenital heart disease, car-
diomyopathy, secondary heart disease such as rheumatic
fever or Kawasaki’s disease), risk factors for cardiovascular
disease (such as arrhythmia or hypertension), muscular
dystrophy or unexplained skeletal muscle weakness, any
diagnosis that could affect cardiac function or lead to
myocardial fibrosis, and renal dysfunction (glomerular
filtration rate <75 ml/min assessed on day of scan) or
other contraindication to CMR with gadolinium.
Two DMD participants were excluded for inadequate
images. Two control participants were excluded for abnor-
mal CMRs (bicuspid aortic valve and pericardial effusion)
and one was excluded for inadequate images.
Study procedure
Pertinent DMD clinical data were collected from the elec-
tronic medical record. For the control group, a phone
screening was performed to assess suitability, including
comprehensive questioning on past and family medical
history. Prior to the CMR, the participant completed a
health risk assessment. All participants provided a blood
sample for measurement of hematocrit on day of CMR.
Cardiovascular magnetic resonance
CMR was performed on a 1.5 Tesla Siemens Avanto
(Siemens Healthcare Sector, Erlangen, Germany) with an
8 channel cardiac coil. Functional imaging was per-
formed as previously described using balanced steady-
state free precession (bSSFP) imaging [13]. Breath-held,
T2-weighted (effective TE 60 ms) double inversion turbo
spin-echo imaging was performed prior to contrast
administration.
The control group and a subset of DMD participants
underwent T2 mapping using a breath-held, electrocar-
diogram (ECG)-triggered, bSSFP sequence with motion
correction. Typical imaging parameters were as follows:
Adiabatic T2 preparation with 35° flip angle, field of view
340 × 272 mm2, matrix size 192 × 144, slice thickness
8 mm, voxel size 1.8 × 1.9 × 8.0 mm3, TR/TE 2.5 ms/
1.1 ms, parallel imaging factor of 2. Intravenous Gd-
DTPA contrast (gadopentate dimeglumine, Magnevist®,
Bayer Healthcare Pharmaceuticals, Wayne, NJ, USA) was
administered through a peripheral intravenous line (PIV)
at a dose of 0.2 mmol/kg. Multiple LGE techniques were
used to insure detection of enhancement: 1) single shot
and 2) segmented inversion recovery bSSFP with opti-
mized inversion recovery to null the signal from the myo-
cardium, and 3) phase sensitive inversion recovery bSSFP
with an inversion time of 300 ms.
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Breath-held modified Look-Locker inversion recovery
(MOLLI) sequences were performed prior to and
15 min after contrast administration in the mid-
ventricular level in the short axis plane at the same slice
location as the T2 mapping and the T2-weighted, cine,
and LGE imaging [10, 21]. MOLLI sequences were
motion-corrected, ECG-triggered images obtained in
diastole with typical imaging parameters: non-selective
inversion with a 35° flip angle, single shot SSFP imaging,
initial inversion time of 120 ms with 80 ms increments,
field of view 340 × 272 mm2, matrix size 256 × 144, slice
thickness 8 mm, voxel size 1.3 × 1.9 × 8.0 mm3, TR/TE
2.6 ms/1.1 ms, parallel imaging factor of 2. The
matrix size was decreased to 192 × 128 for heart rates >90
(approximate voxel size 1.8 × 2.1 × 8 mm3). The initial
pre-contrast MOLLI acquired 5 images after the first in-
version with a 3 beat pause followed by 3 images after the
second inversion, or 5(3)3. This was later modified to a 3 s
pause, or 5(3 s)3, to reduce bias from higher heart rates;
the post-contrast protocol was acquired at a 4(1)3(1)2
[22]. Motion correction as described by Xue, et al. was
performed and a T1 map was generated on the scanner
[23]. A goodness of fit map was also performed in most
participants at the time of the scan to evaluate data qual-
ity. One investigator (JS) was present for all scans and
reviewed the MOLLI sequences with the technologist for
adequacy at the time of the scan. Any image felt to be in-
adequate due to poor breath holds or poor motion correc-
tion was repeated at the time of the scan.
Image processing
One reader (JS) traced all contours in this study. LV vol-
ume, mass, and function were calculated as previously
described [13]. The presence or absence of LGE was
qualitatively assessed by one reader and confirmed by a
second reader. T2 maps were contoured to obtain global
myocardial T2.
T1 maps, obtained prior to and after contrast adminis-
tration as described by Messroghli et al., [21] were used
along with the subject’s hematocrit to calculate an ECV
map using software programmed in MATLAB 2014a (The
MathWorks, Natick, MA, USA). Affine two-dimensional
image registration was performed using a normalized mu-
tual information cost and search function. Native and
post-contrast T1 maps were registered to the native T1
map. The field of view was cropped to the region of inter-
est to prevent spurious maximization of mutual informa-
tion that would result in poor alignment. In cases of
suboptimal T1 map image registration on the scanner, the
sequence was either repeated without motion correction
or image registration was performed using MATLAB
software. T1 maps were computed from magnitude recon-
structed MR data using iterative sign inversion Levenberg-
Marquardt optimization, as complex data were not
available. This process results in multiple optimizations
and T1 estimates per voxel. The best fit, and therefore
best estimate of T1, was determined by the optimization
that had the smallest root mean squared error. Affine
two-dimensional image registration was again used and all
image frames, both pre and post-contrast, were registered
to the first pre-contrast frame for consistency. The T1 and
ECV calculations were validated using an a priori defined
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Regions of interest (ROIs) were manually drawn on T1
and ECV maps within the LV mesocardium in 6 seg-
ments using the standard AHA/ACC model of segmen-
tation (Fig. 2) [24]. Global myocardial T1 and ECV
values were calculated from segmental values. ROIs were
carefully traced to avoid partial volume averaging with
blood-pool or epicardial fat. Based on the T1 mapping
consensus statement, areas of LGE were included in the
ROIs as these areas were felt to be the most focal areas
in a continuum of diffuse ECM expansion [10]. For cases
where the ROIs were difficult to trace, LGE images were
used to help trace the ROIs. Imaging artifact was not
contoured. Segments were not included in the analysis if
the bounds of the myocardium could not be distin-
guished from surrounding tissue and blood pool or if
image registration was inadequate in those segments. In
order to assess the ECV of large areas of LGE, targeted
ROIs were traced in areas of clear LGE on ECV maps.
These ROIs were confirmed by a second reader (DP).
A random sample of 10 ECV maps was re-contoured by
a separate reader (DP) to assess inter-observer variability.
The same sample was re-contoured by the initial reader
one month later to assess intra-observer variability.
The quality of each ECV map was graded using
methods reported by Kellman et al. [14] whereby ECV
maps were assigned a score ranging from 1 to 5, with 1
representing a non-diagnostic map and 5 representing
an excellent map. None of the maps with a score less
than 3 were included.
Statistical analysis
Demographic variables were compared using either a
Wilcoxon rank-sum (continuous variables) or a Chi-
square or Fisher’s exact test (categorical variables). In-
ter- and intra-observer variability were assessed using
an intraclass correlation coefficient. Correlations between
continuous variables were evaluated using Spearman’s rho
(2 variables) or linear regression (controlling for multiple
variables). The segmental and global native T1 and ECV
were compared between groups using Wilcoxon rank-
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sum tests. Subset analyses included comparisons of DMD
participants with normal LVEF (≥55 %) and without LGE
to controls. The variance of ECV measurements within
each segment was calculated by squaring the standard de-
viation. We then averaged the variances from each seg-
ment and took the square root, which estimates the
average within-subject standard deviation.
Analyses were performed with IBM SPSS statistics,
version 22.0 (Armonk, NY: IBM Corp). Study data were
collected and managed using REDCap (Research Elec-
tronic Data Capture) electronic data capture tools
hosted at Vanderbilt [25].
Results
Demographics
The study enrolled 31 DMD and 11 healthy participants.
The DMD participants were younger than the controls
(Table 1). DMD participants had faster heart rates and
were shorter and weighed less, resulting in smaller body
surface areas. There were no other significant demo-
graphic differences.
LV volume and function
The DMD group had a lower LVEF than controls
(54.8 % ± 8.1 vs 60.3 % ± 2.7, p = 0.033) (Table 2). All
control participants had normal LVEF (≥55 %). Twelve
of the 31 DMD participants (38.7 %) had abnormal
LVEF. All DMD participants with abnormal LVEF had re-
gional wall motion abnormalities; 21 DMD participants
had regional wall motion abnormalities. The DMD group
had a smaller indexed left ventricular end diastolic volume
(63.8 ml/m2 ± 14.8 vs 79.3 ml/m2 ± 11.0, p = 0.001). This is
consistent with the minimal early LV dilatation previously
reported in DMD [26]. There were no other significant
differences in chamber dimensions.
Late gadolinium enhancement
No control patients had LGE. Nineteen of the 31 DMD
participants had LGE in at least one segment (Table 2);




Fig. 1 Validation of T1 and ECV mapping software. To confirm that
our results were quantitatively correct, we generated a simulated
dataset for both pre and post-contrast data. In this dataset, we use
inversion times of 120, 1018, 1698, 3125 milliseconds and 280, 693,
755, 1860 milliseconds for pre and post-contrast data respectively. A
hematocrit value of 0.45 was used. Three different pseudo regions of
interest (ROIs) were generated to simulate the blood pool and two
left ventricular ROIs. This simulated data is generated such that we ex-
pect the following T1 times for the following regions: T1pre_blood-
pool = 1498.3 ms, T1pre_LV1 = 1054.7 ms and T1pre_LV2 = 1393.6 ms,
T1post_bloodpool = 419.7 ms, T1post_LV1 = 529.7 ms, and T1post_
LV2 = 419.7 ms. We also expect ECV values for the following regions to
be 0.55, 0.33, and 0.60 respectively. The results in (a), (b), and (c) match
with the a priori defined dataset
Soslow et al. Journal of Cardiovascular Magnetic Resonance  (2016) 18:5 Page 4 of 13
slice used for T1 mapping. Eighteen of the 19 DMD par-
ticipants with LGE had regional wall motion abnormal-
ities. DMD participants with LGE had significantly
lower LVEF than DMD without LGE (51.5 % ± 8.6 vs
60.2 % ± 2.7, p = 0.001). All 12 DMD participants with ab-
normal LVEF had at least one segment with LGE. LGE
was present in 7 DMD participants with normal LVEF.
T2-weighted images and T2 mapping
No significant edema was detected by subjective analysis
of T2-weighted imaging. All controls and 12 DMD partici-
pants underwent T2 mapping. The mean T2 values for
both DMD and control participants were not suggestive
of myocardial edema and were lower in DMD compared
with control (47 ms ± 2 vs 49 ms ± 1, p < 0.001).
T1 mapping and extracellular volume
For native T1 maps, 99.2 % of segments were contoured;
99.6 % of segments on ECV maps were contoured. For
the ROIs of LGE performed on ECV maps, 15 of 19 had
ROIs contoured. The remaining 4 either had no LGE at
that particular slice location or had such a small area of
LGE that contouring was not possible. The quality of
DMD ECV maps was excellent in 15 participants
(48.4 %), good in 13 participants (41.9 %), and adequate
in 3 participants (9.7 %). The ECV quality in controls
was excellent in 7 participants (63.6 %) and good in 4
participants (36.4 %). The ECV map quality did not dif-
fer significantly between DMD and controls (p = 0.475).
Figure 3 shows example native T1 maps and ECV
maps, with corresponding LGE images. The mean native
T1 value was significantly higher in DMD than in con-
trols (1045 ms ± 57 vs 988 ms ± 14, p = 0.001) (Table 3,
Fig. 4a). These differences remained significant when
comparing DMD participants with normal LVEF
(1039 ms ± 49 vs 988 ms ± 14, p = 0.002) and DMD par-
ticipants without LGE (1038 ms ± 55 vs 988 ms ± 14,
p = 0.011) (Fig. 4b, c).
ECV values demonstrated excellent intra- and inter-
observer agreement (ICC = 0.963 for inter-observer,
ICC = 0.957 for intra-observer, p < 0.001 for both).
When compared with controls, DMD participants had sig-
nificantly increased ECV (0.31 ± 0.05 vs 0.24 ± 0.01,
p < 0.001) (Fig. 5a, Table 3). When comparing LVEF-
normal DMD participants with controls, this difference
remained significant (0.28 ± 0.03 vs 0.24 ± 0.01, p < 0.001)
(Fig. 5b). LGE-negative DMD participants had a signifi-
cantly higher ECV than controls (0.29 ± 0.03 vs 0.24 ±
0.01, p = 0.001) (Fig. 5c). DMD participants with systolic
dysfunction had a greater mean ECV than DMD partici-
pants with normal function (0.35 ± 0.05 vs 0.28 ± 0.03,
p < 0.001). There was no significant difference in ECV
between DMD participants with and without LGE
(0.32 ± 0.05 vs 0.29 ± 0.03, p = 0.306). However, 3 of those
Fig. 2 Example regions of interest. Example regions of interest drawn on extracellular volume map in a Duchenne muscular dystrophy participant
with late gadolinium enhancement primarily in the subepicardium of the free wall
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participants had no LGE in the mid-ventricular slice pos-
ition used for T1 mapping. When DMD subjects were di-
vided into those with visible LGE at the mid-ventricular
slice and those without, those with visible LGE had signifi-
cantly elevated ECV (0.33 ± 0.05 vs 0.29 ± 0.03, p = 0.03).
The mean ECV of the targeted ROIs of LGE was signifi-
cantly higher than the ECV of DMD participants without
LGE (0.51 ± 0.08 vs 0.29 ± 0.03, p < 0.001). The range of
ECV in these targeted ROIs was 0.39 to 0.63. DMD partic-
ipants had a higher within subject standard deviation of
ECV compared with controls (0.039 vs 0.024, p < 0.001).
DMD participants without LGE also had a higher within
subject standard deviation of ECV compared with controls
(0.033 vs 0.024, p = 0.001).
There was no correlation between duration of angioten-
sin converting enzyme inhibitor, angiotensin receptor
blocker, or beta-blocker therapy and either native T1 or
ECV in DMD participants. There was a trend towards a
negative correlation between duration of corticosteroids
and ECV (rho = −0.351, p = 0.053), but this did not reach
statistical significance. There was no difference in ECV be-
tween DMD participants with more than 6 months of
steroid therapy and those with less than 6 months of ther-
apy. There was a negative correlation between ECV and
heart rates (r = −0.463, p = 0.009) suggesting that higher
heart rates are associated with lower ECV. However, when
adjusting for use of beta-blockers or LVEF, this association
was no longer significant. There was no significant associ-
ation between native T1 and heart rate within DMD (p =
0.345). There was a significant negative correlation be-
tween heart rate and T2 (r = −0.64, p = 0.025), though
DMD participants with heart rates less than 100 bpm also
had T2 values below the mean of controls (47 ms vs
49 ms, p < 0001). Global ECV had a significant negative
correlation with LVEF (rho = −0.618, p < 0.001).
Table 1 Demographics
Control DMDa
N = 11 N = 31
Age (years) 24.5 ± 3.9 (range 18–30) 13.4 ± 4.7 (range 8–27)
Male Gender (%) 100 % 100 %
Height (cm) 182 ± 8 144 ± 15
Weight (kg) 76 ± 9 51 ± 16
BSAb (m2) 2.0 ± 0.2 1.4 ± 0.3
BMIc (kg/m2) 23.0 ± 1.5 24.1 ± 6.3
Heart Rate (bpm) 66 ± 4 94 ± 14
Ambulatory (%) 11 (100 %) 7 (22.6 %)
Ventilatory support (%) 0 % 7 (22.6 %)
Race
Caucasian 8 (72.7 %) 27 (87.1 %)
African American 1 (9.1 %) 2 (6.5 %)
Asian 1 (9.1 %) 2 (6.5 %)
Other 0 0
Mixed 1 (9.1 %) 0
Hispanic/Latino 1 (9.1 %) 3 (9.7 %)
Medical Therapy at CMRd
ACEie 0 % 14 (45.2 %)
ARBf 0 % 5 (16.1 %)
β-blocker 0 % 10 (32.3 %)
Corticosteroids 0 % 21 (67.7 %)
Corticosteroid
duration (years)
0 3.7 ± 3.2
aDuchenne muscular dystrophy (DMD)
bBody surface area (BSA)
cBody mass index (BMI)
dCardiovascular Magnetic Resonance (CMR)
eAngiotensin Converting Enzyme Inhibitor (ACEi)
fAngiotensin Receptor Blocker (ARB)
Table 2 Cardiac MRI findings in control and Duchenne
muscular dystrophy (DMD) participants
Control DMDa p-value
N = 11 N = 31
LVEFb (%) 60.3 ± 2.7 54.8 ± 8.1 0.033
Indexed LVEDVc (ml/m2) 79.3 ± 11.0 63.8 ± 14.8 0.001
Indexed LVESVd (ml/m2) 33.2 ± 4.8 29.4 ± 11.1 0.062
Indexed LV mass (g/m2) 58.3 ± 8.0 53.2 ± 10.1 0.058
RVEFe (%) 56.1 ± 3.4 56.6 ± 5.1 0.552
LGEf abnormal 0 19 (61.3 %) <0.001#
Basal Anterior 0 4 (12.9 %)
Basal Anteroseptal 0 1 (3.2 %)
Basal Inferoseptal 0 3 (9.7 %)
Basal Inferior 0 12 (38.7 %)
Basal Inferolateral 0 18 (58.1 %)
Basal Anterolateral 0 18 (58.1 %)
Mid Anterior 0 6 (19.4 %)
Mid Anteroseptal 0 3 (9.7 %)
Mid Inferoseptal 0 5 (16.1 %)
Mid Inferior 0 13 (41.9 %)
Mid Inferolateral 0 17 (54.8 %)
Mid Anterolateral 0 16 (51.6 %)
Apical Anterior 0 5 (16.1 %)
Apical Septal 0 6 (19.4 %)
Apical Inferior 0 5 (16.1 %)
Apical Lateral 0 7 (22.6 %)
Apex 0 3 (9.7 %)
#Fisher’s exact test (rest Wilcoxon rank-sum)
aDuchenne muscular dystrophy (DMD)
bLeft ventricular ejection fraction (LVEF)
cLeft ventricular end diastolic volume (LVEDV)
dLeft ventricular end systolic volume (LVESV)
eRight ventricular ejection fraction (RVEF)
fLate gadolinium enhancement (LGE)
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When analyzing the entire cohort, linear regression
demonstrated no change in the association between glo-
bal ECV and diagnosis when correcting for age, height,
weight, or heart rate (Table S1, Additional file 1). There
was also no change in the association between native T1
and diagnosis when correcting for age, height, or heart
rate (Table S2, Additional file 1). There was a correlation
between weight and native T1 using multivariable re-
gression with no association between native T1 and
diagnosis. The significance of this finding is unclear.
Discussion
The abnormalities in native T1 and ECV are consistent
with a diffuse expansion of ECM, a known pathological
finding in DMD. These abnormalities were detectable
even in participants without LGE. This has significance
because native T1 and ECV mapping may provide early,
non-invasive biomarkers of DMD myocardial disease
(Fig. 6). This earlier detection may allow for the initi-
ation of more timely disease specific therapy. ECV map-
ping also has potential to assess the efficacy of therapy
before systolic dysfunction develops and may provide a
surrogate outcome measure in clinical trials. This is the
first manuscript of which we are aware that has compre-
hensively and prospectively evaluated native T1 and
ECV mapping in DMD.
This study expands on our previous, retrospective
work evaluating post-contrast T1 mapping [13]. The
present prospective analysis suggests that native T1 and
ECV are robust indicators of DMD myocardial disease.
While native T1 values can be obtained without contrast
administration, they are prone to site-to-site variability
in the T1 mapping protocol, as well as inter-individual
variability in heart rate. Because the ECV mapping proto-
col is ratiometric, the ECV measurement may be more
generalizable across sites [10]. Which method better pre-
dicts morbidity and mortality will need to be explored.
However, the results of this study strongly support the
value of a systematic, prospective investigation of these
potential biomarkers.
The increased within subject standard deviation of
ECV suggests that there are areas of myocardium with
Fig. 3 Example cardiac MRI images. 1) Healthy control without late gadolinium enhancement (LGE) (a), normal native T1 (b), and ECV (c) values.
2) Duchenne muscular dystrophy (DMD) participant with significant LGE (d) (arrows); native T1 map (e) demonstrates increased T1; ECV map (f)
demonstrates similar areas of elevated ECV (arrows) as the LGE. 3) LGE image in DMD participant without LGE (g) but with diffusely elevated
native T1 (h) and ECV (i) suggesting extracellular matrix expansion
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less ECM expansion that are adjacent to areas of the
myocardium with more ECM expansion. This increased
variation is consistent with known ultrastructural find-
ings in DMD [27]. This is the first time, to our know-
ledge, that a non-invasive imaging method has detected
a potential corollary to these subtle ultrastructural
changes. Whether this increased variability impacts mor-
bidity, such as arrhythmia, remains to be determined in
future studies.
The results of this study are similar to those of Florian
et al., who evaluated patients with Becker muscular dys-
trophy (BMD) who were significantly older (mean age of
35 years vs 13.4 years in this study) [20]. The BMD pa-
tients without LGE did not have increased ECV com-
pared with controls. In contrast, DMD subjects without
cardiac involvement in our study still had elevated mean
ECV. It is unclear if this represents a difference in the
progression of Becker and DMD cardiomyopathy or if
this is due to the larger number of patients without LGE
in our study. The T1 and ECV values of DMD and con-
trol participants had significant overlap. This overlap
was expected as the study enrolled DMD participants
along the entire spectrum of disease (Fig. 6). Moreover,
this overlap is desirable; identification of DMD partici-
pants with no ECM expansion will be equally important
for research and clinical care.
The mean ECV value of all LGE-positive DMD partici-
pants was not significantly increased compared with that
of LGE-negative DMD participants. This likely resulted
from conservative ROIs and the variable distribution of
LGE; not all DMD participants had LGE in the same
slice location as the T1 mapping. When analysis was
limited to DMD participants with LGE in the same slice
location, the ECV in DMD participants with LGE was
significantly increased compared to those without LGE.
Moreover, the ECV in targeted ROIs of LGE was signifi-
cantly elevated compared to participants without LGE.
Fatty infiltration and edema of DMD myocardium
have the potential to affect T1 mapping and ECV values
[27, 28]. None of the participants had chest pain or
other cardiac complaints at the time of their CMR, so
the likelihood that superimposed myocarditis is con-
founding our interpretation seems low. Myocardial fat
and edema were not detected qualitatively using a
double inversion recovery turbo fast spin echo nor quanti-
tatively using T2 mapping. No patient in the study had vis-
ible fat or edema on these images. Of note, 5 DMD
participants had native T1 values less than 900 ms in 6
total segments. These lower values did not appear to be
due to contamination with epicardial fat and no myocar-
dial fat was visible in T2-weighted imaging, though further
evaluation for myocardial fat deposition may be warranted
in future studies. While lower T2 values may have been af-
fected by heart rate, DMD participants with heart rates less
than 100 bpm had T2 values below the mean of controls.
These findings, paired with the high ECV within areas of
LGE, suggest that the larger areas of LGE in this study
were due to fibrosis and not edema or inflammation.
Pathological studies in DMD suggest that diffuse
microscopic fibrosis is present in most boys, and
authors have suggested that this fibrosis precedes mani-
fest systolic dysfunction [8, 29]. While we hypothesize
that larger focal areas of fibrosis on LGE images are ir-
reversible, studies suggest that this diffuse microscopic
fibrosis can improve with therapy, creating a window of
opportunity for earlier therapy in DMD [30–32]. ECV
mapping allows detection of this diffuse fibrosis and
ECV values correlate well with histological specimens
[16, 17, 33, 34]. ECV has also been linked to outcomes
in other disease processes [19, 35]. However, before its
widespread adoption in clinical care or as an outcome
measure, further evaluation in DMD must be per-
formed. Serial follow up is necessary to assess the
change in ECV over time. An association between ECV
and DMD arrhythmia or mortality will need to be
established and documentation of stabilization or im-
provement in ECV with medical therapy is essential.
Our data suggest, however, that native T1 and ECV
mapping in DMD are promising, non-invasive bio-
markers of this progressive myocardial disease.
Table 3 Difference in global native T1, ECV, and global T2 between Duchenne Muscular Dystrophy (DMD) participants and controls
Control DMDa p-value* DMD normal LVEFb p-value* DMD no LGEc p-value*
(N = 11) (N = 31) (N = 19) (N = 12)
Native T1 (ms) 988 ± 14 1045 ± 57 0.001 1039 ± 49 0.002 1038 ± 55 0.011
ECVd 0.24 ± 0.01 0.31 ± 0.05 <0.001 0.28 ± 0.03 <0.001 0.29 ± 0.03 0.001
Control DMD p-value*
(n = 11) (n = 12)
T2 (ms) 49 ms ± 1 47 ± 2 <0.001
*p-values for comparison with controls using Wilcoxon rank-sum
aDuchenne muscular dystrophy (DMD)
bLeft ventricular ejection fraction (LVEF)
cLate gadolinium enhancement (LGE)
dExtracellular volume fraction (ECV)
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Fig. 4 Scatterplots of global and segmental native T1 values in Duchenne Muscular Dystrophy (DMD) and controls. (a) All DMD participants
compared with controls, (b) DMD participants with normal left ventricular ejection fraction (LVEF) compared with controls, and (c) DMD
participants without late gadolinium enhancement (LGE) compared with controls
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Fig. 5 Scatterplots of global and segmental Extracellular Volume Fraction (ECV) values in Duchenne Muscular Dystrophy (DMD) and controls.
a All DMD participants compared with controls, (b) DMD participants with normal left ventricular ejection fraction (LVEF) compared with controls,
and (c) DMD participants without late gadolinium enhancement (LGE) compared with controls
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Limitations
This is a single center study and in principle, this could
make the results less generalizable. The Neuromuscular-
Cardiology Clinic at our institution, however, draws
DMD patients from across the country, and a large per-
centage of DMD patients are followed in a small number
of centers similar to ours. The primary objective of this
study was the detection of ECM expansion and not the
identification of modifiers of this expansion; therefore,
adjustment for medications was not performed. More-
over, because the study included control participants not
taking any medications, the analysis could not be ad-
justed for current medications. We evaluated the effects
of medications within the DMD population, though this
analysis was likely underpowered, and this adjustment
will be important for any analysis performed exclusively
in DMD participants. Studies with a larger numbers of
patients, likely multi-center, will be necessary to deter-
mine the effects of medications on ECM expansion, but
this is beyond the scope of the current manuscript. The
heart rates were significantly faster in DMD subjects.
However, data suggest that the heart rate effects on T1
mapping are minimized with the sequence parameters
used in this study [22]. Interestingly, there was a signifi-
cant negative correlation between heart rate and ECV,
suggesting that higher heart rates were associated with
lower ECV. While this may have made it more difficult to
achieve statistical significance, we suspect that this associ-
ation is related to confounding from severity of disease; the
association was no longer significant after correction for ei-
ther beta-blocker usage or LVEF. There was no significant
correlation between heart rate and native T1. The T2 values
of DMD participants did correlate with heart rate and this
may have led to some bias. The negative association be-
tween weight and native T1 may be related to myocardial
fat deposition and should be explored in future studies.
Gadolinium contrast agents were not administered to
healthy children in order to minimize the potential for
adverse events. Therefore, the ages of the control group
did not match perfectly with that of the DMD group.
The progressive nature of DMD cardiomyopathy, how-
ever, suggests that older DMD participants are at higher
risk of ECM expansion. Moreover, ECV does not vary
significantly with age in healthy controls [36]. Because of
the difficulty in obtaining CMR without anesthesia or
sedation in young children, the youngest age of DMD
participants was 8 years. The reported ECVs were only
in the 6 myocardial segments at the mid portion of the
LV; we anticipate that increasing the myocardial cover-
age will improve sensitivity.
Fig. 6 Duchenne muscular dystrophy (DMD) results in impaired molecular function prior to abnormal LV systolic function. Cardiomyopathy
progresses with extracellular matrix (ECM) expansion, fibrosis, and manifest LV dysfunction. Standard imaging has limited ability to detect
abnormalities before LV dysfunction (a). Extracellular volume fraction (ECV) mapping can provide a quantitative, early biomarker of DMD
cardiomyopathy (b)
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Conclusions
Our data demonstrate that native T1 and ECV maps can
detect subclinical ECM expansion in DMD participants.
These techniques may provide much needed surrogate
outcome measures in DMD cardiovascular disease.
Additional file
Additional file 1: Table S1. Linear regression of association between
global Extracellular Volume Fraction and diagnosis (Duchenne Muscular
Dystrophy = 1 vs Control = 2) controlling for age, height, weight, or
heart rate. Table S2. Linear regression of association between global
native T1 and diagnosis (Duchenne Muscular Dystrophy = 1 vs Control = 2)
controlling for age, height, weight, or heart rate. (DOCX 47 kb)
Abbreviations
bSSFP: Balanced steady state free precession; CMR: Cardiovascular magnetic
resonance; DMD: Duchenne muscular dystrophy; ECG: Electrocardiogram;
ECM: Extracellular matrix; ECV: Extracellular volume fraction; LGE: Late
gadolinium enhancement; LV: Left ventricular; LVEF: Left ventricular ejection
fraction; MOLLI: Modified Look-Locker inversion recovery; T1: Longitudinal
relaxation time constant.
Competing interests
The authors have no relationship with industry or competing interests.
Authors’ contributions
JHS helped conceive and design study, performed and analyzed CMRs,
contributed to statistical analysis, and drafted and revised the manuscript.
SD wrote MatLab software, contributed to CMR analysis, helped draft and
revise manuscript. KC enrolled patients and collected clinical information,
helped analyze data, and helped critically revise manuscript with important
intellectual content. ML helped conceive study, contributed to image
analysis, and helped critically revise manuscript with important intellectual
content. JCS and MX designed and performed biostatistical analysis, helped
critically revise manuscript with important intellectual content. AA helped
design study, contributed to training JHS in performing and analyzing T1
mapping, helped critically revise manuscript with important intellectual
content. DS contributed to initial study planning and data interpretation,
and helped critically revise manuscript with important intellectual content.
DP performed data collection and analysis, helped critically revise manuscript
with important intellectual content. BD helped with study design and
conception, co-wrote MatLab software, helped draft and revise manuscript.
LM contributed to study conception, design, and analysis, provided DMD
specific knowledge and insight, helped draft and revise manuscript. All
authors read and approved the final manuscript.
Acknowledgments
The authors would like to acknowledge the developers of the pulse
sequence and reconstruction software: Bruce Spottiswoode, Andreas Greiser,
Hui Xue, Christopher Glielmi, Shivraman Giri, and Randall Kroeker.
Funding
This work was supported by American Heart Association Grant
13CRP14530007 (Soslow) (Dallas, TX).
Research reported in this publication was supported by the National Heart,
Lung, and Blood Institute of the National Institutes of Health under Award
Number K23HL123938 (Bethesda, MD) (Soslow). The content is solely the
responsibility of the authors and does not necessarily represent the official
views of the National Institutes of Health.
The project was supported by the National Center for Research Resources,
Grant UL1 RR024975-01, and is now at the National Center for Advancing
Translational Sciences, Grant 2 UL1 TR000445-06 (Bethesda, MD). The content
is solely the responsibility of the authors and does not necessarily represent
the official views of the NIH.
This project was supported by the Fighting Duchenne Foundation and the
Fight DMD/Jonah & Emory Discovery Grant (Nashville, TN) (Markham).
The sponsors and funders had no role in the design and conduct of the
study or in the collection, analysis, and interpretation of the data, or in the
preparation, review, or approval of the manuscript.
Author details
1Thomas P Graham Jr. Division of Pediatric Cardiology, Department of
Pediatrics, Monroe Carell Jr. Children’s Hospital, Vanderbilt University Medical
Center, 2200 Children’s Way Suite 5230, Doctors’ Office Tower, Nashville, TN
37232-9119, USA. 2Department of Electrical Engineering and Computer
Sciences, Vanderbilt University, Nashville, TN, USA. 3Division of Cardiovascular
Medicine, Department of Medicine, Vanderbilt University Medical Center,
Nashville, TN, USA. 4Department of Biostatistics, Vanderbilt University Medical
Center, Nashville, TN, USA. 5National Heart, Lung and Blood Institute (NHLBI),
National Institutes of Health (NIH), Bethesda, MD, USA. 6Department of
Cardiac Services, Maine Medical Center, Portland, ME, USA. 7Department of
Radiology and Radiological Sciences, Vanderbilt University Medical Center,
Nashville, TN, USA. 8Department of Molecular Physiology and Biophysics,
Vanderbilt University, Nashville, TN, USA. 9Department of Biomedical
Engineering, Vanderbilt University, Nashville, TN, USA.
Received: 10 September 2015 Accepted: 11 January 2016
References
1. Dooley J, Gordon KE, Dodds L, MacSween J. Duchenne muscular dystrophy: a
30-year population-based incidence study. Clin Pediatr (Phila). 2010;49(2):177–9.
doi:10.1177/0009922809347777.
2. Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of
cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol. 1990;26(3):271–7.
3. Bach JR, Martinez D. Duchenne muscular dystrophy: continuous noninvasive
ventilatory support prolongs survival. Respir Care. 2011;56(6):744–50.
doi:10.4187/respcare.00831.
4. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Becane HM. Effect of
perindopril on the onset and progression of left ventricular dysfunction in
Duchenne muscular dystrophy. J Am Coll Cardiol. 2005;45(6):855–7.
5. Hor KN, Mazur W, Taylor MD, Al-Khalidi HR, Cripe LH, Jefferies JL, et al. Effects of
steroids and angiotensin converting enzyme inhibition on circumferential
strain in boys with Duchenne muscular dystrophy: a cross-sectional and
longitudinal study utilizing cardiovascular magnetic resonance. J Cardiovasc
Magn Reson. 2011;13:60. doi:10.1186/1532-429X-13-60.
6. Frankel KA, Rosser RJ. The pathology of the heart in progressive muscular
dystrophy: epimyocardial fibrosis. Hum Pathol. 1976;7(4):375–86.
7. Silva MC, Meira ZM, Gurgel Giannetti J, da Silva MM, Campos AF, Barbosa Mde
M, et al. Myocardial delayed enhancement by magnetic resonance imaging in
patients with muscular dystrophy. J Am Coll Cardiol. 2007;49(18):1874–9.
8. Puchalski MD, Williams RV, Askovich B, Sower CT, Hor KH, Su JT, et al. Late
gadolinium enhancement: precursor to cardiomyopathy in Duchenne
muscular dystrophy? Int J Cardiovasc Imaging. 2009;25(1):57–63.
doi:10.1007/s10554-008-9352-y.
9. Hor KN, Taylor MD, Al-Khalidi HR, Cripe LH, Raman SV, Jefferies JL, et al.
Prevalence and distribution of late gadolinium enhancement in a large
population of patients with Duchenne muscular dystrophy: effect of age
and left ventricular systolic function. J Cardiovasc Magn Reson. 2013;15(1):
107. doi:10.1186/1532-429X-15-107.
10. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, et al.
Myocardial T1 mapping and extracellular volume quantification: a Society for
Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the
European Society of Cardiology consensus statement.
J Cardiovasc Magn Reson. 2013;15:92. doi:10.1186/1532-429X-15-92.
11. Broberg CS, Chugh SS, Conklin C, Sahn DJ, Jerosch-Herold M. Quantification
of diffuse myocardial fibrosis and its association with myocardial
dysfunction in congenital heart disease. Circ Cardiovasc Imaging. 2010;3(6):
727–34. doi:10.1161/CIRCIMAGING.108.842096.
12. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, et al.
Equilibrium contrast cardiovascular magnetic resonance for the measurement
of diffuse myocardial fibrosis: preliminary validation in humans. Circulation.
2010;122(2):138–44. doi:10.1161/CIRCULATIONAHA.109.930636.
13. Soslow JH, Damon BM, Saville BR, Lu Z, Burnette WB, Lawson MA, et al.
Evaluation of post-contrast myocardial t1 in duchenne muscular dystrophy
using cardiac magnetic resonance imaging. Pediatr Cardiol. 2015;36(1):49–56.
doi:10.1007/s00246-014-0963-x.
Soslow et al. Journal of Cardiovascular Magnetic Resonance  (2016) 18:5 Page 12 of 13
14. Kellman P, Wilson JR, Xue H, Ugander M, Arai AE. Extracellular volume
fraction mapping in the myocardium, part 1: evaluation of an automated
method. J Cardiovasc Magn Reson. 2012;14:63. doi:10.1186/1532-429X-14-63.
15. Miller CA, Naish JH, Bishop P, Coutts G, Clark D, Zhao S, et al.
Comprehensive validation of cardiovascular magnetic resonance techniques
for the assessment of myocardial extracellular volume. Circ Cardiovasc
Imaging. 2013;6(3):373–83. doi:10.1161/CIRCIMAGING.112.000192.
16. White SK, Sado DM, Fontana M, Banypersad SM, Maestrini V, Flett AS, et al.
T1 mapping for myocardial extracellular volume measurement by CMR:
bolus only versus primed infusion technique. JACC. 2013;6(9):955–62.
doi:10.1016/j.jcmg.2013.01.011.
17. aus dem Siepen F, Buss SJ, Messroghli D, Andre F, Lossnitzer D, Seitz S, et al.
T1 mapping in dilated cardiomyopathy with cardiac magnetic resonance:
quantification of diffuse myocardial fibrosis and comparison with
endomyocardial biopsy. Eur Heart J Cardiovasc Imaging. 2015;16(2):210–6.
doi:10.1093/ehjci/jeu183.
18. Kellman P, Wilson JR, Xue H, Bandettini WP, Shanbhag SM, Druey KM, et al.
Extracellular volume fraction mapping in the myocardium, part 2: initial clinical
experience. J Cardiovasc Magn Reson. 2012;14:64. doi:10.1186/1532-429X-14-64.
19. Wong TC, Piehler K, Meier CG, Testa SM, Klock AM, Aneizi AA, et al.
Association between extracellular matrix expansion quantified by
cardiovascular magnetic resonance and short-term mortality. Circulation.
2012;126(10):1206–16. doi:10.1161/CIRCULATIONAHA.111.089409.
20. Florian A, Ludwig A, Rosch S, Yildiz H, Sechtem U, Yilmaz A. Myocardial fibrosis
imaging based on T1-mapping and extracellular volume fraction (ECV)
measurement in muscular dystrophy patients: diagnostic value compared with
conventional late gadolinium enhancement (LGE) imaging. Eur Heart J
Cardiovasc Imaging. 2014;15(9):1004–12. doi:10.1093/ehjci/jeu050.
21. Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU,
Ridgway JP. Modified Look-Locker inversion recovery (MOLLI) for high-
resolution T1 mapping of the heart. Magn Reson Med. 2004;52(1):141–6.
doi:10.1002/mrm.20110.
22. Kellman P, Hansen MS. T1-mapping in the heart: accuracy and precision.
J Cardiovasc Magn Reson. 2014;16:2. doi:10.1186/1532-429X-16-2.
23. Xue H, Shah S, Greiser A, Guetter C, Littmann A, Jolly MP, et al. Motion
correction for myocardial T1 mapping using image registration with
synthetic image estimation. Magn Reson Med. 2012;67(6):1644–55.
doi:10.1002/mrm.23153.
24. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al.
Standardized myocardial segmentation and nomenclature for tomographic
imaging of the heart: a statement for healthcare professionals from the
Cardiac Imaging Committee of the Council on Clinical Cardiology of the
American Heart Association. Circulation. 2002;105(4):539–42.
25. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
electronic data capture (REDCap)–a metadata-driven methodology and
workflow process for providing translational research informatics support.
J Biomed Inform. 2009;42(2):377–81. doi:10.1016/j.jbi.2008.08.010.
26. Mazur W, Hor KN, Germann JT, Fleck RJ, Al-Khalidi HR, Wansapura JP et al.
Patterns of left ventricular remodeling in patients with Duchenne Muscular
Dystrophy: a cardiac MRI study of ventricular geometry, global function, and
strain. Int J Cardiovasc Imaging. 2011. doi:10.1007/s10554-010-9781-2.
27. Sanyal SK, Johnson WW, Thapar MK, Pitner SE. An ultrastructural basis for
electrocardiographic alterations associated with Duchenne's progressive
muscular dystrophy. Circulation. 1978;57(6):1122–9.
28. Mavrogeni S, Papavasiliou A, Spargias K, Constandoulakis P, Papadopoulos
G, Karanasios E, et al. Myocardial inflammation in Duchenne Muscular
Dystrophy as a precipitating factor for heart failure: a prospective study.
BMC Neurol. 2010;10:33. doi:10.1186/1471-2377-10-33.
29. Hunter S. The heart in muscular dystrophy. Br Med Bull. 1980;36(2):133–4.
30. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial
fibrosis in patients with hypertensive heart disease. Circulation.
2000;102(12):1388–93.
31. Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T, et al.
Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic
dysfunction and myocardial fibrosis in mildly symptomatic patients with
idiopathic dilated cardiomyopathy: a pilot study. Circulation. 2005;112(19):
2940–5. doi:10.1161/CIRCULATIONAHA.105.571653.
32. Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL.
Losartan-dependent regression of myocardial fibrosis is associated with
reduction of left ventricular chamber stiffness in hypertensive patients.
Circulation. 2002;105(21):2512–7.
33. de Meester de Ravenstein C, Bouzin C, Lazam S, Boulif J, Amzulescu M,
Melchior J, et al. Histological Validation of measurement of diffuse interstitial
myocardial fibrosis by myocardial extravascular volume fraction from
Modified Look-Locker imaging (MOLLI) T1 mapping at 3 T. J Cardiovasc
Magn Reson. 2015;17:48. doi:10.1186/s12968-015-0150-0.
34. Fontana M, White SK, Banypersad SM, Sado DM, Maestrini V, Flett AS, et al.
Comparison of T1 mapping techniques for ECV quantification. Histological
validation and reproducibility of ShMOLLI versus multibreath-hold T1
quantification equilibrium contrast CMR. J Cardiovasc Magn Reson.
2012;14:88. doi:10.1186/1532-429X-14-88.
35. Wong TC, Piehler KM, Kang IA, Kadakkal A, Kellman P, Schwartzman DS, et al.
Myocardial extracellular volume fraction quantified by cardiovascular
magnetic resonance is increased in diabetes and associated with mortality
and incident heart failure admission. Eur Heart J. 2014;35(10):657–64.
doi:10.1093/eurheartj/eht193.
36. Dabir D, Child N, Kalra A, Rogers T, Gebker R, Jabbour A, et al. Reference values
for healthy human myocardium using a T1 mapping methodology: results
from the International T1 Multicenter cardiovascular magnetic resonance
study. J Cardiovasc Magn Reson. 2014;16:69. doi:10.1186/s12968-014-0069-x.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Soslow et al. Journal of Cardiovascular Magnetic Resonance  (2016) 18:5 Page 13 of 13
